Explore four top ETFs for 2024, including healthcare, water infrastructure, and biotech sectors. These investments offer diversification, affordability, and growth potential, suitable for seasoned and beginner investors alike. Proper research and expert advice are recommended to navigate market volatility and industry risks effectively.

Leading ETF Picks for 2024: Four Investment Vehicles to Consider

Investors increasingly favor exchange-traded funds (ETFs) for portfolio diversification. ETFs provide enhanced liquidity and lower costs compared to mutual funds, appealing to both beginners and seasoned investors.

Similar to stocks, ETFs often experience frequent trades and market fluctuations. With around 19,000 ETFs available nationwide, selecting the best options can be daunting. Here are four prominent ETFs to consider this year.

Vanguard Healthcare ETF
As a top player among US ETF providers, Vanguard offers highly trusted investment options.

Vanguard Healthcare (VHC) focuses on a rapidly growing sector with long-term growth potential. Its steady profitability stems from increasing healthcare expenses and ongoing industry expansion. Known for affordability, VHC includes over 380 companies, such as Johnson & Johnson, UnitedHealth Group, and Merck & Co.

Compared to similar funds, VHC features a lower risk profile, making it a dependable choice for health sector investors. Its annual expense ratio of just 0.1% translates to about $10 annually per $10,000 invested.

Tortoise Water Infrastructure ETF
In light of recent droughts and climate issues, water infrastructure firms are gaining prominence. Launched in 2018, Tortoise Water Infrastructure ETF is a niche, promising long-term opportunity. It invests in companies involved in water supply systems, treatment facilities, and wastewater management.

Key holdings include Pentair and Aqua America. With an expense ratio around 0.4%, this ETF offers a focused investment option for those interested in sustainable resource development beyond tech giants.

Loncar Cancer Immunotherapy ETF
For investors aiming at innovative healthcare sectors, this ETF emphasizes cancer research and immunotherapy firms. It comprises 30 stocks, with major holdings like Merck, Novartis, and MorphoSys.

While it carries higher risk due to biotech clinical trial uncertainties, the potential for substantial long-term gains makes it attractive. Its expense ratio is about 0.79%.

ETFs are favored for their low costs and diversification benefits over mutual funds. Still, industry volatility requires ongoing monitoring. Proper research and possibly expert advice are vital for selecting the best ETFs aligned with your financial goals.

Thorough analysis and professional guidance can help investors choose suitable ETF options, ensuring a more informed and secure investment journey.